Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Nongenitourinary complications associated with robot-assisted laparoscopic and radical retropubic prostatectomy: A single institution assessment of 1,100 patients over 11 years.

Brooks NA, Boland RS, Strigenz ME, Mott SL, Brown JA.

Urol Oncol. 2018 Nov;36(11):501.e9-501.e13. doi: 10.1016/j.urolonc.2018.07.017. Epub 2018 Aug 25.

PMID:
30153970
2.

Pilot Study to Determine Optimal Stent Duration Following Ureteroscopy: Three versus Seven days.

Paul CJ, Brooks NA, Ghareeb GM, Tracy CR.

Curr Urol. 2018 Feb;11(2):97-102. doi: 10.1159/000447201. Epub 2017 Dec 30.

3.

Increasing the size of ureteral access sheath during retrograde intrarenal surgery improves surgical efficiency without increasing complications.

Tracy CR, Ghareeb GM, Paul CJ, Brooks NA.

World J Urol. 2018 Jun;36(6):971-978. doi: 10.1007/s00345-018-2204-z. Epub 2018 Jan 27.

PMID:
29380131
4.

Testosterone Therapy: Review of Clinical Applications.

Petering RC, Brooks NA.

Am Fam Physician. 2017 Oct 1;96(7):441-449. Review.

5.

Bladder Neck Contracture Following Radical Retropubic versus Robotic-Assisted Laparoscopic Prostatectomy.

Spector BL, Brooks NA, Strigenz ME, Brown JA.

Curr Urol. 2017 Aug;10(3):145-149. doi: 10.1159/000447169. Epub 2017 Jul 30.

6.

Mohs Melanoma Chemosurgery Simplified to a Single Brief Caustic Application: Possible Vaccine Effect.

Brooks NA.

Dermatol Surg. 2018 Feb;44(2):311-313. doi: 10.1097/DSS.0000000000001175. No abstract available.

7.

Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications for Cystectomy in Bladder Cancer.

Tobert CM, Hamilton-Reeves JM, Norian LA, Hung C, Brooks NA, Holzbeierlein JM, Downs TM, Robertson DP, Grossman R, Nepple KG.

J Urol. 2017 Sep;198(3):511-519. doi: 10.1016/j.juro.2017.01.087. Epub 2017 Mar 9. Review.

8.

Pushing Stones Uphill: Why Patients Are Lost to Follow-Up After Uncomplicated Ureteroscopy.

Brooks NA, Paul CJ, Ghareeb GM, Tracy CR.

J Endourol. 2017 Feb;31(2):135-140. doi: 10.1089/end.2016.0675.

PMID:
28049356
9.

Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.

Steinberg RL, Brooks NA, Thomas LJ, Mott SL, O'Donnell MA.

Urol Oncol. 2017 May;35(5):201-207. doi: 10.1016/j.urolonc.2016.11.016. Epub 2016 Dec 29.

PMID:
28041998
10.

Treatment options in non-muscle-invasive bladder cancer after BCG failure.

Brooks NA, O'Donnell MA.

Indian J Urol. 2015 Oct-Dec;31(4):312-9. doi: 10.4103/0970-1591.166475. Review.

11.

Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.

Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, Gilmour R, Graff JR, Jambrina E, Mader M, McCann D, Na S, Parsons SH, Pratt SE, Shih C, Stancato LF, Starling JJ, Tate C, Velasco JA, Wang Y, Ye XS.

Mol Cancer Ther. 2014 Feb;13(2):364-74. doi: 10.1158/1535-7163.MCT-13-0513. Epub 2013 Dec 19.

12.

Mohs micrographic surgery for the treatment of melanoma.

Hui AM, Jacobson M, Markowitz O, Brooks NA, Siegel DM.

Dermatol Clin. 2012 Jul;30(3):503-15. doi: 10.1016/j.det.2012.04.010. Epub 2012 Jun 5. Review.

PMID:
22800554
13.

Three-minute chemosurgical biopsy site treatment for invasive cutaneous melanoma.

Brooks NA.

Dermatol Surg. 2012 Jun;38(6):968-9. doi: 10.1111/j.1524-4725.2012.02411.x. No abstract available.

PMID:
22642459
14.

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.

Bradbury RH, Hales NJ, Rabow AA, Walker GE, Acton DG, Andrews DM, Ballard P, Brooks NA, Colclough N, Girdwood A, Hancox UJ, Jones O, Jude D, Loddick SA, Mortlock AA.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5442-5. doi: 10.1016/j.bmcl.2011.06.122. Epub 2011 Jul 2.

PMID:
21782422
15.

Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors.

Wang Z, Watt W, Brooks NA, Harris MS, Urban J, Boatman D, McMillan M, Kahn M, Heinrikson RL, Finzel BC, Wittwer AJ, Blinn J, Kamtekar S, Tomasselli AG.

Biochim Biophys Acta. 2010 Sep;1804(9):1817-31. doi: 10.1016/j.bbapap.2010.05.007. Epub 2010 May 24.

PMID:
20580860
16.

A membrane penetrating multiple antigen peptide (MAP) incorporating ovalbumin CD8 epitope induces potent immune responses in mice.

Brooks NA, Pouniotis DS, Sheng KC, Apostolopoulos V, Pietersz GA.

Biochim Biophys Acta. 2010 Dec;1798(12):2286-95. doi: 10.1016/j.bbamem.2010.05.007. Epub 2010 May 15.

17.

Chemosurgery for invasive melanoma.

Brooks NA.

Dermatol Surg. 2010 Feb;36(2):237-40. doi: 10.1111/j.1524-4725.2009.01397.x. Epub 2009 Dec 18. No abstract available.

PMID:
20039917
18.

Cell-penetrating peptides: application in vaccine delivery.

Brooks NA, Pouniotis DS, Tang CK, Apostolopoulos V, Pietersz GA.

Biochim Biophys Acta. 2010 Jan;1805(1):25-34. doi: 10.1016/j.bbcan.2009.09.004. Epub 2009 Sep 25. Review.

PMID:
19782720
19.

IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease.

Staschke KA, Dong S, Saha J, Zhao J, Brooks NA, Hepburn DL, Xia J, Gulen MF, Kang Z, Altuntas CZ, Tuohy VK, Gilmour R, Li X, Na S.

J Immunol. 2009 Jul 1;183(1):568-77. doi: 10.4049/jimmunol.0802361.

20.

Type 2 diabetes: lifestyle changes and drug treatment.

Brooks NA.

Virtual Mentor. 2009 Mar 1;11(3):237-41. doi: 10.1001/virtualmentor.2009.11.3.cprl1-0903. No abstract available.

Supplemental Content

Loading ...
Support Center